We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TREATMENT OF HEPATITIS C IN DIALYSIS PATIENTS WITH PEGYLATED INTERFERON ALFA-2A - SINGLE DIALYSIS CENTER EXPERIENCE.
- Authors
Ćorić, Aida; Resić, Halima; Vukobrat-Bijedić, Zora; Avdić, Emir; Šahović, Vahidin; Mašnić, Fahrudin; Kukavica, Nihad
- Abstract
Hepatitis C in dialysis patients is a "silent" nature of chronic infection that often can be the initial stage and go unnoticed. Start of viremic phase is usually associated with the activity of ALT (up to 70-74 U / L) and precedes seroconversion. This is followed by a constant viraemia, normal ALT activity and anti-HCV positivity. Past research and experience show that about 25% of patients with HCV infection have normal ALT values, not just of patients with hemodialysis, while 40% have a minimum deviation from the normal ALT values. In the treatment of hepatitis C in patients with end stage, renal failure indicated the application of recombinant interferon alfa-2a or pegylated interferon. 1. Involve group in dialysis patients with chronic hepatitis C infection, which is the indication for treatment according to the protocol of treatment of chronic hepatitis C in hemodialysis patients. 2. Involve dialysis patients with a positive qualitative and quantitative HCV RNA PCR, 3. Provide special monitoring of dialysis patients who were included in the therapeutic protocol, to follow regular treatment, side effects of treatment and outcome of treatment. The target population for treatment was 13 patients in the terminal stage of renal failure on chronic hemodialysis treatment, age group between 32 and 63 years, with chronic hepatitis C infection (12 patients had anti-HCV positive for more than a year and more). One patient had only antigenemia HBs positive and one patient was with dual infection. Patients have a different genotypes of virus C, only one patient had genotype 1a of hepatitis C, one patient had genotype 3, five patients had genotype 1b, four patients had genotype 4, one patient had not determine genotype of virus C. All patients had treated with pegylated interferon alfa -2a Pegylated interferon alfa -2a with reduced dose a 135 ug or 90 ug one time on week. All treatments last 48 weeks. Only three patients after the therapy had a negative PCR after six months and a year of control remained negative. Three PCR negative patients were infected with genotype 1b. (23,07 %). Mean age was 49,23± 8,82 years, and mean hemodialysis duration 144,92± 55,74 months. Conclusion: Treated patients showed heterogeneity in their study of group (different genotypes of hepatitis C). During of the treatment the patients have not demonstrated any major complications. The clinical picture of chronic hepatitis is usually mild, with slight variations in the values of biochemical parameters. Treatment of chronic hepatitis gives perspective and better patient candidates for kidney transplantation.
- Subjects
HEPATITIS C treatment; HEMODIALYSIS patients; INTERFERONS; SEROCONVERSION; ANTIVIRAL agents; VIREMIA; POLYMERASE chain reaction; KIDNEY transplantation
- Publication
Medical Journal / Medicinski Žurnal, 2011, Vol 17, Issue 4, p304
- ISSN
1512-5866
- Publication type
Article